Mehmet Sofuoglu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11672135/publications.pdf

Version: 2024-02-01

136 papers	6,332 citations	50276 46 h-index	76900 74 g-index
136 all docs	136 docs citations	136 times ranked	5551 citing authors

#	Article	IF	Citations
1	The Effect of Cannabis Compared with Alcohol on Driving. American Journal on Addictions, 2009, 18, 185-193.	1.4	272
2	Cognitive enhancement as a treatment for drug addictions. Neuropharmacology, 2013, 64, 452-463.	4.1	251
3	Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans.. Experimental and Clinical Psychopharmacology, 1999, 7, 274-283.	1.8	234
4	Stress decreases the ability to resist smoking and potentiates smoking intensity and reward. Journal of Psychopharmacology, 2011, 25, 490-502.	4.0	227
5	Neuroscience of Behavioral and Pharmacological Treatments for Addictions. Neuron, 2011, 69, 695-712.	8.1	188
6	REVIEW: Norepinephrine and stimulant addiction. Addiction Biology, 2009, 14, 119-129.	2.6	170
7	The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology, 2013, 227, 177-192.	3.1	165
8	Six-Month Trial of Bupropion With Contingency Management for Cocaine Dependence in a Methadone-Maintained Population. Archives of General Psychiatry, 2006, 63, 219.	12.3	154
9	Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction, 2010, 105, 38-48.	3.3	145
10	Role of progesterone in nicotine addiction: Evidence from initiation to relapse.. Experimental and Clinical Psychopharmacology, 2010, 18, 451-461.	1.8	140
11	Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology, 2018, 16, 403-414.	2.9	137
12	Effects of progesterone treatment on smoked cocaine response in women. Pharmacology Biochemistry and Behavior, 2002, 72, 431-435.	2.9	124
13	The effects of exogenous progesterone on drug craving and stress arousal in cocaine dependence: Impact of gender and cue type. Psychoneuroendocrinology, 2013, 38, 1532-1544.	2.7	124
14	Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacology Biochemistry and Behavior, 2004, 78, 699-705.	2.9	122
15	Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction, 2003, 98, 1625-1632.	3.3	119
16	Treatment Outcome Predictors for Cocaine Dependence. American Journal of Drug and Alcohol Abuse, 2007, 33, 191-206.	2.1	108
17	Novel Approaches to the Treatment of Cocaine Addiction. CNS Drugs, 2005, 19, 13-25.	5.9	107
18	Sex steroid hormones, stress response, and drug craving in cocaine-dependent women: Implications for relapse susceptibility.. Experimental and Clinical Psychopharmacology, 2007, 15, 445-452.	1.8	107

#	Article	IF	Citations
19	The Impact of Cigarette Smoking on Stimulant Addiction. American Journal of Drug and Alcohol Abuse, 2009, 35, 12-17.	2.1	98
20	Rapid Nicotine Clearance is Associated with Greater Reward and Heart Rate Increases from Intravenous Nicotine. Neuropsychopharmacology, 2012, 37, 1509-1516.	5.4	98
21	Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opinion on Emerging Drugs, 2006, 11, 91-98.	2.4	91
22	Progesterone treatment during the early follicular phase of the menstrual cycle: Effects on smoking behavior in women. Pharmacology Biochemistry and Behavior, 2001, 69, 299-304.	2.9	87
23	Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug and Alcohol Dependence, 2007, 87, 1-9.	3.2	85
24	Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders. Journal of Dual Diagnosis, 2016, 12, 90-106.	1.2	78
25	Subjective, Physiological, and Cognitive Responses to Intravenous Nicotine: Effects of Sex and Menstrual Cycle Phase. Neuropsychopharmacology, 2014, 39, 1431-1440.	5.4	73
26	A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation. Journal of Psychopharmacology, 2015, 29, 300-311.	4.0	66
27	Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers. Psychoneuroendocrinology, 2011, 36, 123-132.	2.7	65
28	A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. Neuropsychopharmacology, 2015, 40, 2813-2821.	5.4	64
29	Pharmacological treatments for methamphetamine addiction: current status and future directions. Expert Review of Clinical Pharmacology, 2017, 10, 1-10.	3.1	63
30	Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug and Alcohol Dependence, 2018, 192, 264-270.	3.2	62
31	Cholinergic Functioning in Stimulant Addiction. CNS Drugs, 2009, 23, 939-952.	5.9	61
32	A critical review of the literature on attentional bias in cocaine use disorder and suggestions for future research.. Experimental and Clinical Psychopharmacology, 2014, 22, 469-483.	1.8	60
33	Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug and Alcohol Dependence, 2000, 60, 69-76.	3.2	59
34	Effects of progesterone stimulated allopregnanolone on craving and stress response in cocaine dependent men and women. Psychoneuroendocrinology, 2016, 65, 44-53.	2.7	58
35	Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug and Alcohol Dependence, 2003, 69, 273-282.	3.2	57
36	Cognitive function as an emerging treatment target for marijuana addiction.. Experimental and Clinical Psychopharmacology, 2010, 18, 109-119.	1.8	57

#	Article	IF	Citations
37	Gender Differences in the Prevalence of Fibromyalgia and in Concomitant Medical and Psychiatric Disorders: A National Veterans Health Administration Study. Journal of Women's Health, 2018, 27, 1035-1044.	3.3	57
38	Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokers. Human Psychopharmacology, 2009, 24, 559-564.	1.5	56
39	Self-Administration of Intravenous Nicotine in Male and Female Cigarette Smokers. Neuropsychopharmacology, 2008, 33, 715-720.	5.4	55
40	Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. Psychopharmacology, 2011, 213, 61-68.	3.1	55
41	Prediction of Treatment Outcome by Baseline Urine Cocaine Results and Selfâ€Reported Cocaine Use for Cocaine and Opioid Dependence. American Journal of Drug and Alcohol Abuse, 2003, 29, 713-727.	2.1	54
42	Pharmacological and Behavioral Treatment of Opioid Use Disorder. Psychiatric Research and Clinical Practice, 2019, 1, 4-15.	2.4	53
43	Effects of Labetalol Treatment on the Physiological and Subjective Response to Smoked Cocaine. Pharmacology Biochemistry and Behavior, 2000, 65, 255-259.	2.9	52
44	Pharmacological treatment of comorbid PTSD and substance use disorder: Recent progress. Addictive Behaviors, 2014, 39, 428-433.	3.0	52
45	Perspectives on neurocognitive rehabilitation as an adjunct treatment for addictive disorders. Progress in Brain Research, 2016, 224, 345-369.	1.4	50
46	E-cigarettes, alcohol use, and mental health: Use and perceptions of e-cigarettes among college students, by alcohol use and mental health status. Addictive Behaviors, 2019, 91, 12-20.	3.0	50
47	Future pharmacological treatments for substance use disorders. British Journal of Clinical Pharmacology, 2014, 77, 382-400.	2.4	48
48	Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence. Journal of Clinical Psychiatry, 2018, 79, 17m11669.	2.2	44
49	Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology, 2006, 184, 645-651.	3.1	43
50	Subjective responses to intravenous nicotine: Greater sensitivity in women than in men.. Experimental and Clinical Psychopharmacology, 2009, 17, 63-69.	1.8	42
51	Inhalation of Alcohol Vapor: Measurement and Implications. Alcoholism: Clinical and Experimental Research, 2017, 41, 238-250.	2.4	41
52	The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users. Addictive Behaviors, 2005, 30, 1125-1134.	3.0	40
53	Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study. Lancet Psychiatry,the, 2014, 1, 360-367.	7.4	40
54	Depressive symptoms modulate the subjective and physiological response to cocaine in humans. Drug and Alcohol Dependence, 2001, 63, 131-137.	3.2	38

#	Article	IF	Citations
55	Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology, 2005, 181, 504-510.	3.1	38
56	Galantamine improves sustained attention in chronic cocaine users.. Experimental and Clinical Psychopharmacology, 2011, 19, 11-19.	1.8	37
57	Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. Clinical Psychological Science, 2019, 7, 1190-1206.	4.0	36
58	The effects of alcohol-containing e-cigarettes on young adult smokers. Drug and Alcohol Dependence, 2016, 159, 272-276.	3.2	33
59	Tobacco and alcohol use disorders: Evaluating multimorbidity. Addictive Behaviors, 2018, 78, 59-66.	3.0	33
60	Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacology Biochemistry and Behavior, 2003, 75, 801-808.	2.9	32
61	The reinforcement threshold for nicotine as a target for tobacco control. Drug and Alcohol Dependence, 2012, 125, 1-7.	3.2	32
62	Cognitive rehabilitation for individuals with opioid use disorder: A randomized controlled trial. Neuropsychological Rehabilitation, 2019, 29, 1273-1289.	1.6	32
63	Progesterone effects on cocaine use in male cocaine users maintained on methadone: A randomized, double-blind, pilot study.. Experimental and Clinical Psychopharmacology, 2007, 15, 453-460.	1.8	31
64	Atomoxetine Attenuates Dextroamphetamine Effects in Humans. American Journal of Drug and Alcohol Abuse, 2009, 35, 412-416.	2.1	31
65	Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans. Pharmacology Biochemistry and Behavior, 2009, 92, 135-140.	2.9	31
66	Attentional bias in opioid users: A systematic review and meta-analysis. Drug and Alcohol Dependence, 2018, 191, 270-278.	3.2	30
67	Intravenous Nicotine Self-Administration in Smokers: Doseâ€"Response Function and Sex Differences. Neuropsychopharmacology, 2016, 41, 2034-2040.	5.4	29
68	Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. Psychopharmacology, 2012, 224, 413-420.	3.1	28
69	Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology, 2009, 207, 153-162.	3.1	27
70	Prevalence and correlates of co-prescribing psychotropic medications with long-term opioid use nationally in the Veterans Health Administration. Psychiatry Research, 2015, 227, 324-332.	3.3	27
71	Exclusion of participants based on substance use status: Findings from randomized controlled trials of treatments for PTSD. Behaviour Research and Therapy, 2017, 89, 33-40.	3.1	27
72	Pharmacologic management of relapse prevention in addictive disorders. Psychiatric Clinics of North America, 2004, 27, 627-648.	1.3	26

#	Article	IF	Citations
73	Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals. Journal of Psychopharmacology, 2015, 29, 312-323.	4.0	26
74	Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review. CNS Drugs, 2018, 32, 421-435.	5.9	26
75	Modulation of â€œProtectiveâ€•Nicotine Perception and Use Profile by Flavorants: Preliminary Findings in E-cigarettes. Nicotine and Tobacco Research, 2020, 22, 771-781.	2.6	26
76	Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology, 2019, 236, 2857-2866.	3.1	25
77	Cocaine Withdrawal Symptoms Predict Medication Response in Cocaine Users. American Journal of Drug and Alcohol Abuse, 2006, 32, 617-627.	2.1	24
78	Effects of Galantamine on Cocaine Use in Chronic Cocaine Users. American Journal on Addictions, 2011, 20, 302-303.	1.4	24
79	Stress and opioid use disorder: A systematic review. Addictive Behaviors, 2019, 98, 106010.	3.0	24
80	Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study. Psychoneuroendocrinology, 2017, 86, 96-103.	2.7	22
81	The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs, 2018, 32, 981-996.	5.9	22
82	Riluzole and d-amphetamine interactions in humans. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 16-22.	4.8	21
83	Comparisons of Cocaine-Only, Opioid-Only, and Users of Both Substances in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Substance Use and Misuse, 2016, 51, 553-564.	1.4	21
84	Targeting neuroinflammation with minocycline in heavy drinkers. Psychopharmacology, 2019, 236, 3013-3021.	3.1	20
85	Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine and Tobacco Research, 2003, 5, 947-953.	2.6	19
86	Impact of E-cigarettes on Smoking and Related Outcomes in Veteran Smokers With Psychiatric Comorbidity. Journal of Dual Diagnosis, 2018, 14, 2-13.	1.2	19
87	Individual Differences in the Subjective Response to Smoked Cocaine in Humans. American Journal of Drug and Alcohol Abuse, 2000, 26, 591-602.	2.1	18
88	Tiagabine affects the subjective responses to cocaine in humans. Pharmacology Biochemistry and Behavior, 2005, 82, 569-573.	2.9	18
89	Effects of endogenous and exogenous progesterone on emotional intelligence in cocaineâ€dependent men and women who also abuse alcohol. Human Psychopharmacology, 2014, 29, 589-598.	1.5	18
90	Effects of phenytoin on cocaine self-administration in humans1Portions of this report were presented at the 59th Annual Scientific Meeting of the College on the Problems of Drug Dependence, Nashville, June 1997.1. Drug and Alcohol Dependence, 1999, 53, 273-275.	3.2	17

#	Article	IF	Citations
91	Modafinil and nicotine interactions in abstinent smokers. Human Psychopharmacology, 2008, 23, 21-30.	1.5	17
92	Biological Treatments for Amfetamine Dependence. CNS Drugs, 2007, 21, 851-869.	5.9	16
93	Disulfiram enhances subjective effects of dextroamphetamine in humans. Pharmacology Biochemistry and Behavior, 2008, 90, 394-398.	2.9	16
94	NEuro COgnitive REhabilitation for Disease of Addiction (NECOREDA) Program: From Development to Trial. Basic and Clinical Neuroscience, 2015, 6, 291-8.	0.6	16
95	Rates and Correlates of Pain Specialty Clinic Use Nationally in the Veterans Health Administration. Pain Medicine, 2017, 18, pnw206.	1.9	15
96	Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. Journal of Substance Abuse Treatment, 2019, 107, 29-37.	2.8	14
97	Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only. American Journal of Drug and Alcohol Abuse, 2019, 45, 527-537.	2.1	14
98	Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder. Nicotine and Tobacco Research, 2022, 24, 3-9.	2.6	14
99	Acute effects of inhaled menthol on the rewarding effects of intravenous nicotine in smokers. Journal of Psychopharmacology, 2018, 32, 986-994.	4.0	13
100	Doubleâ€Blind Placeboâ€Controlled Trial of Galantamine for Methadoneâ€Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal on Addictions, 2019, 28, 238-245.	1.4	13
101	Effect of Menthol-preferring Status on Response to Intravenous Nicotine. Tobacco Regulatory Science (discontinued), 2016, 2, 317-328.	0.2	12
102	Effects of galantamine on smoking behavior and cognitive performance in treatmentâ€seeking smokers prior to a quit attempt. Human Psychopharmacology, 2018, 33, e2665.	1.5	11
103	Sex Differences in Opioid Use Disorder Prevalence and Multimorbidity Nationally in the Veterans Health Administration. Journal of Dual Diagnosis, 2021, 17, 124-134.	1.2	11
104	Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. Behavioural Pharmacology, 2006, 17, 731-735.	1.7	10
105	Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. Pharmacology Biochemistry and Behavior, 2019, 181, 86-92.	2.9	10
106	Differential effects of nicotine delivery rate on subjective drug effects, urges to smoke, heart rate and blood pressure in tobacco smokers. Psychopharmacology, 2020, 237, 1359-1369.	3.1	10
107	Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects. Pharmacology Biochemistry and Behavior, 2017, 159, 55-61.	2.9	9
108	E-cigarette nicotine dose and flavor: Relationship with appeal, choice, and tobacco use amongst veterans with comorbid psychiatric disorders. Addictive Behaviors, 2019, 92, 53-57.	3.0	9

#	Article	IF	Citations
109	Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. Drug and Alcohol Dependence, 2021, 228, 109097.	3.2	9
110	Neurocognitive Function as a Treatment Target for Tobacco Use Disorder. Current Behavioral Neuroscience Reports, 2017, 4, 10-20.	1.3	8
111	How Intravenous Nicotine Administration in Smokers Can Inform Tobacco Regulatory Science. Tobacco Regulatory Science (discontinued), 2016, 2, 452-463.	0.2	7
112	Stress response genes and the severity of nicotine withdrawal. Pharmacogenomics, 2016, 17, 1-3.	1.3	7
113	Baseline executive functions and receiving cognitive rehabilitation can predict treatment response in people with opioid use disorder. Journal of Substance Abuse Treatment, 2021, 131, 108558.	2.8	7
114	Catecholâ€oâ€methyltransferase gene Val158met polymorphism as a potential predictor of response to computerâ€assisted delivery of cognitiveâ€behavioral therapy among cocaineâ€dependent individuals: Preliminary findings from a randomized controlled trial. American Journal on Addictions, 2015, 24, 443-451.	1.4	6
115	Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial. Drug and Alcohol Dependence, 2018, 186, 130-137.	3.2	6
116	Biochemical, demographic, and self-reported tobacco-related predictors of the acute heart rate response to nicotine in smokers. Pharmacology Biochemistry and Behavior, 2018, 173, 36-43.	2.9	6
117	Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers. Psychopharmacology, 2021, 238, 2083-2090.	3.1	6
118	Treatment outcomes in individuals diagnosed with comorbid opioid use disorder and Posttraumatic stress disorder: A review. Addictive Behaviors, 2021, 122, 107026.	3.0	6
119	Toward Refinement of Our Understanding of the Fundamental Nature of Addiction. Biological Psychiatry, 2016, 80, 172-173.	1.3	5
120	Carvedilol does not reduce cocaine use in methadone-maintained cocaine users. Journal of Substance Abuse Treatment, 2017, 73, 63-69.	2.8	5
121	Naturalistic measurement of dual cue attentional bias in moderate to heavy-drinking smokers: A preliminary investigation. Drug and Alcohol Dependence, 2020, 209, 107892.	3.2	5
122	Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study. American Journal of Drug and Alcohol Abuse, 2020, 46, 812-822.	2.1	4
123	Prevalence and correlates of coprescribing anxiolytic medications with extensive prescription opioid use in Veterans Health Administration patients with metastatic cancer. Journal of Opioid Management, 2016, 12, 259-268.	0.5	4
124	Atomoxetine in abstinent cocaine users: Sex differences. Data in Brief, 2017, 14, 566-572.	1.0	3
125	Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. Addiction Biology, 2022, 27, e13161.	2.6	3
126	Progesterone Increases Nicotine Withdrawal and Anxiety in Male but Not Female Smokers During Brief Abstinence. Nicotine and Tobacco Research, 2022, 24, 1898-1905.	2.6	3

#	Article	IF	Citations
127	Receptivity to a peer counselling program and recovery atmosphere as perceived by Veterans Health Administration peer support specialists and supervisors. American Journal of Psychiatric Rehabilitation, 2017, 20, 62-73.	0.7	2
128	Stimulants and Mood Disorders. Current Addiction Reports, 2018, 5, 323-329.	3.4	2
129	Pharmacological cognitive enhancers. , 2020, , 303-320.		1
130	Acute effects of inhaled menthol on cognitive effects of intravenous nicotine among young adult cigarette smokers. Addictive Behaviors, 2021, 122, 107022.	3.0	1
131	Reply: Response to Letter to the Editor. Neuropsychopharmacology, 2008, 33, 2044-2044.	5.4	0
132	Commentary on Ling etâ€ƒal. (2012): The PROMETAâ„¢ treatment does not reduce methamphetamine use. Addiction, 2012, 107, 370-371.	3.3	0
133	The Opioid Crisis: Filling in the Picture. Psychiatric Research and Clinical Practice, 2019, 1, 2-3.	2.4	0
134	GABAergic Agents for the Treatment of Nicotine Dependence. , 2006, , 177-186.		0
135	Plasma Menthol Glucuronide as a Biomarker for the Behavioral Effects of Menthol and Nicotine in Humans. Frontiers in Pharmacology, 2022, 13, 844824.	3.5	0
136	Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. Psychopharmacology, 2022, 239, 2809-2818.	3.1	0